BSTC - BioSpecifics Technologies Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

BioSpecifics Technologies Corp.

35 Wilbur Street
Lynbrook, NY 11563
United States
516-593-7000
http://www.biospecifics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Mr. J. Kevin BuchiChief Exec. OfficerN/AN/A1955
Mr. Patrick M. CaldwellPrincipal Accounting OfficerN/AN/A1962
Dr. Ronald Law J.D., Ph.D.Sr. VP of Bus. Devel.N/AN/A1953
Carl A. ValensteinCorp. Sec.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, and human lipoma, as well as uterine fibroids. In addition, the company engages in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. BioSpecifics Technologies Corp. has a development and license agreement with Endo Global Ventures. The company was founded in 1957 and is headquartered in Lynbrook, New York.

Corporate Governance

BioSpecifics Technologies Corp.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 3; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.